Guggenheim analyst Vamil Divan upgraded Jade Biosciences (JBIO) to Buy from Neutral with a $14 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences presents JADE101 preclinical data at ERA Congress
- Is AVTE a Buy, Before Earnings?
- Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership
- Jade Biosciences Updates Corporate Presentation
- Jade Biosciences initiated with an Outperform at Wedbush